27841784|t|Conventional and Iontophoresis Corneal Cross-Linking for Keratoconus: Efficacy and Assessment by Optical Coherence Tomography and Confocal Microscopy
27841784|a|To compare the efficacy, safety, and microstructural corneal changes during 2 years after conventional corneal collagen cross-linking (C - CXL) and transepithelial corneal CXL by iontophoresis (I - CXL) for keratoconus. Eighty eyes of 80 patients with progressive keratoconus were treated by C - CXL (n = 40) or I - CXL (n = 40). Patients were investigated before surgery and 1, 3, 6, 12, and 24 months after treatment. We measured central corneal thickness and maximal simulated keratometry values (Kmax) and performed specular microscopy and in vivo confocal microscopy at each time point. The demarcation line was assessed 1 month after treatment. Kmax remained stable after I - CXL during the entire study period (P = 0.56), whereas the average keratometry increased by 0.2 diopter (50.9 ± 5.6-51.1 ± 5.2). Kmax significantly decreased 1 (P = 0.02) to 2 years (P < 0.01) after C - CXL, with an average decrease of 1.1 diopters (49.9 ± 4.5-48.8 ± 4.2). The failure rate of I - CXL was 20% and that of C - CXL 7.5%. The demarcation line was superficially visible in 35% of cases after I - CXL compared with 95% of cases after C - CXL. Endothelial cell density and central corneal thickness remained stable during the entire study period. The change in Kmax 2 years after C - CXL and I - CXL and the preoperative Kmax were negatively correlated (r = 0.14, P = 0.013, and r = 0.17, P = 0.007, respectively). I - CXL halted progression of keratoconus less efficiently than did C - CXL after 2 years of follow-up. Longer prospective studies are still needed to ensure I - CXL efficacy.
27841784	0	12	Conventional	T080	C0439858
27841784	17	30	Iontophoresis	T061	C0022024
27841784	31	52	Corneal Cross-Linking	T061	C4065848
27841784	57	68	Keratoconus	T047	C0022578
27841784	70	78	Efficacy	T080	C2348767
27841784	83	93	Assessment	T058	C0220825
27841784	97	125	Optical Coherence Tomography	T060	C0920367
27841784	130	149	Confocal Microscopy	T059	C0242842
27841784	153	160	compare	T052	C1707455
27841784	165	173	efficacy	T080	C2348767
27841784	175	181	safety	T061	C1269689
27841784	203	210	corneal	T023	C0010031
27841784	211	218	changes	T169	C0392747
27841784	219	225	during	T079	C0347984
27841784	226	233	2 years	T079	C0439234
27841784	234	239	after	T079	C0687676
27841784	240	252	conventional	T080	C0439858
27841784	253	283	corneal collagen cross-linking	T061	C4065848
27841784	285	286	C	T080	C0439858
27841784	289	292	CXL	T061	C4065848
27841784	314	325	corneal CXL	T061	C4065848
27841784	329	342	iontophoresis	T061	C0022024
27841784	344	345	I	T061	C0022024
27841784	348	351	CXL	T061	C4065848
27841784	357	368	keratoconus	T047	C0022578
27841784	377	381	eyes	T023	C0015392
27841784	388	396	patients	T101	C0030705
27841784	402	425	progressive keratoconus	T047	C2114756
27841784	431	438	treated	T169	C1522326
27841784	442	443	C	T080	C0439858
27841784	446	449	CXL	T061	C4065848
27841784	462	463	I	T061	C0022024
27841784	466	469	CXL	T061	C4065848
27841784	480	488	Patients	T101	C0030705
27841784	494	506	investigated	T169	C1292732
27841784	507	513	before	T079	C0332152
27841784	514	521	surgery	T061	C0543467
27841784	546	552	months	T079	C0439231
27841784	553	558	after	T079	C0687676
27841784	559	568	treatment	T061	C0087111
27841784	573	581	measured	T080	C0444706
27841784	582	607	central corneal thickness	T201	C1720164
27841784	660	669	performed	T169	C0884358
27841784	670	689	specular microscopy	T060	C4054002
27841784	694	701	in vivo	T082	C1515655
27841784	702	721	confocal microscopy	T059	C0242842
27841784	725	729	each	T081	C1457900
27841784	730	740	time point	T079	C2348792
27841784	746	762	demarcation line	T047	C1443381
27841784	767	775	assessed	T169	C0205245
27841784	776	783	1 month	T079	C4082115
27841784	784	789	after	T079	C0687676
27841784	790	799	treatment	T061	C0087111
27841784	815	821	stable	T080	C0205360
27841784	822	827	after	T079	C0687676
27841784	828	829	I	T061	C0022024
27841784	832	835	CXL	T061	C4065848
27841784	836	842	during	T079	C0347984
27841784	847	853	entire	T081	C0439751
27841784	854	859	study	T062	C2603343
27841784	860	866	period	T079	C1948053
27841784	891	898	average	T081	C1510992
27841784	899	910	keratometry	T058	C3494755
27841784	911	920	increased	T081	C0205217
27841784	924	935	0.2 diopter	T081	C0439484
27841784	980	989	decreased	T081	C0205216
27841784	1006	1013	2 years	T079	C0439234
27841784	1025	1030	after	T079	C0687676
27841784	1031	1032	C	T080	C0439858
27841784	1035	1038	CXL	T061	C4065848
27841784	1048	1055	average	T081	C1510992
27841784	1056	1064	decrease	T081	C0547047
27841784	1068	1080	1.1 diopters	T081	C0439484
27841784	1110	1117	failure	T033	C0162643
27841784	1118	1122	rate	T081	C1521828
27841784	1126	1127	I	T061	C0022024
27841784	1130	1133	CXL	T061	C4065848
27841784	1154	1155	C	T080	C0439858
27841784	1158	1161	CXL	T061	C4065848
27841784	1172	1188	demarcation line	T047	C1443381
27841784	1207	1214	visible	T080	C0205379
27841784	1225	1230	cases	T169	C0868928
27841784	1231	1236	after	T079	C0687676
27841784	1237	1238	I	T061	C0022024
27841784	1241	1244	CXL	T061	C4065848
27841784	1245	1253	compared	T052	C1707455
27841784	1266	1271	cases	T169	C0868928
27841784	1272	1277	after	T079	C0687676
27841784	1278	1279	C	T080	C0439858
27841784	1282	1285	CXL	T061	C4065848
27841784	1287	1311	Endothelial cell density	T033	C0429518
27841784	1316	1341	central corneal thickness	T201	C1720164
27841784	1351	1357	stable	T080	C0205360
27841784	1358	1364	during	T079	C0347984
27841784	1369	1375	entire	T081	C0439751
27841784	1376	1381	study	T062	C2603343
27841784	1382	1388	period	T079	C1948053
27841784	1394	1400	change	T169	C0392747
27841784	1409	1416	2 years	T079	C0439234
27841784	1417	1422	after	T079	C0687676
27841784	1423	1424	C	T080	C0439858
27841784	1427	1430	CXL	T061	C4065848
27841784	1435	1436	I	T061	C0022024
27841784	1439	1442	CXL	T061	C4065848
27841784	1451	1463	preoperative	T079	C0445204
27841784	1474	1484	negatively	T080	C0205556
27841784	1485	1495	correlated	T080	C1707520
27841784	1558	1559	I	T061	C0022024
27841784	1562	1565	CXL	T061	C4065848
27841784	1573	1584	progression	T046	C0242656
27841784	1588	1599	keratoconus	T047	C0022578
27841784	1600	1604	less	T081	C0439092
27841784	1605	1616	efficiently	T080	C0442799
27841784	1626	1627	C	T080	C0439858
27841784	1630	1633	CXL	T061	C4065848
27841784	1634	1639	after	T079	C0687676
27841784	1640	1647	2 years	T079	C0439234
27841784	1651	1660	follow-up	T058	C1522577
27841784	1662	1668	Longer	T080	C0205166
27841784	1669	1688	prospective studies	T062	C0033522
27841784	1699	1705	needed	T080	C0027552
27841784	1716	1717	I	T061	C0022024
27841784	1720	1723	CXL	T061	C4065848
27841784	1724	1732	efficacy	T080	C2348767